Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Singer

Showing results (691-700 of 771) with videos related to

Pageof 78
Sort By:
Journal of the American Heart Association|May 23, 2024
Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF AnalysisJosephine Harrington, Anne S Hellkamp, Kenneth W Mahaffey, et al.
Neurology|July 27, 2007
A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairmentG Schifitto, J Zhang, S R Evans, et al.
Molecular & Cellular Proteomics : MCP|April 22, 2016
Quantitative Tagless Copurification: A Method to Validate and Identify Protein-Protein InteractionsMaxim Shatsky, Ming Dong, Haichuan Liu, et al.
Journal of the American Heart Association|March 26, 2013
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trialDaniel E Singer, Anne S Hellkamp, Jonathan P Piccini, et al.
Circulation. Cardiovascular Quality and Outcomes|June 14, 2013
Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryMichael W Cullen, Sunghee Kim, Jonathan P Piccini, et al.
American Heart Journal|March 25, 2014
Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryEmily C O'Brien, DaJuanicia N Holmes, Jack E Ansell, et al.
Thrombosis Research|April 24, 2017
Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trialYihong Sun, Dayi Hu, Susanna Stevens, et al.
Clinical Cardiology|February 2, 2018
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trialAjar Kochar, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Circulation|June 5, 2014
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jonathan L Halperin, Graeme J Hankey, Daniel M Wojdyla, et al.
Heart (British Cardiac Society)|June 28, 2020
Patterns of oral anticoagulation use with cardioversion in clinical practiceKyle Geurink, DaJuanicia Holmes, Michael D Ezekowitz, et al.
Pageof 78

Showing results (691-700 of 771) with videos related to

Sort By:
Pageof 78
Journal of the American Heart Association|May 23, 2024
Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF AnalysisJosephine Harrington, Anne S Hellkamp, Kenneth W Mahaffey, et al.
Neurology|July 27, 2007
A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairmentG Schifitto, J Zhang, S R Evans, et al.
Molecular & Cellular Proteomics : MCP|April 22, 2016
Quantitative Tagless Copurification: A Method to Validate and Identify Protein-Protein InteractionsMaxim Shatsky, Ming Dong, Haichuan Liu, et al.
Journal of the American Heart Association|March 26, 2013
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trialDaniel E Singer, Anne S Hellkamp, Jonathan P Piccini, et al.
Circulation. Cardiovascular Quality and Outcomes|June 14, 2013
Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryMichael W Cullen, Sunghee Kim, Jonathan P Piccini, et al.
American Heart Journal|March 25, 2014
Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryEmily C O'Brien, DaJuanicia N Holmes, Jack E Ansell, et al.
Thrombosis Research|April 24, 2017
Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trialYihong Sun, Dayi Hu, Susanna Stevens, et al.
Clinical Cardiology|February 2, 2018
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trialAjar Kochar, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Circulation|June 5, 2014
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jonathan L Halperin, Graeme J Hankey, Daniel M Wojdyla, et al.
Heart (British Cardiac Society)|June 28, 2020
Patterns of oral anticoagulation use with cardioversion in clinical practiceKyle Geurink, DaJuanicia Holmes, Michael D Ezekowitz, et al.
Pageof 78